Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. Additionally, the company is advancing UBX1967 for various ophthalmologic conditions, while UBX2050, a human anti-Tie2 agonist monoclonal antibody, also targets age-related eye diseases. Furthermore, UBX2089, an a-Klotho hormone drug candidate, is in development for numerous neurological indications. Established in 2009 as Forge, Inc., the company adopted the name Unity Biotechnology, Inc. in January 2015 and is headquartered in South San Francisco, California.